Amarin Shareholders Reject Key Proposal at AGM

Amarin ( (AMRN) ) has issued an update.

At Amarin Corporation’s Annual General Meeting on May 13, 2025, shareholders voted on several proposals, with all but Proposal 12 being approved. Proposal 12, which aimed to allow the Board to allot 10% of the company’s share capital without statutory pre-emption rights, did not receive the necessary shareholder approval despite recommendations from ISS and Glass Lewis. This rejection necessitates the Board to explore alternative compensation arrangements for non-employee directors, potentially impacting the company’s cash position.

The most recent analyst rating on (AMRN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Amarin stock, see the AMRN Stock Forecast page.

Spark’s Take on AMRN Stock

According to Spark, TipRanks’ AI Analyst, AMRN is a Neutral.

Amarin faces significant financial and market challenges, with declining revenues and profitability issues being key concerns. Technical analysis shows mixed signals, providing no clear direction. The company’s valuation is negative, further detracting from its appeal. However, strategic global expansion and recent positive corporate events offer some potential for future improvement. The overall score reflects these mixed aspects, highlighting both current pressures and future opportunities.

To see Spark’s full report on AMRN stock, click here.

More about Amarin

Amarin Corporation plc operates in the pharmaceutical industry, focusing on the development and commercialization of therapeutics to improve cardiovascular health. The company is known for its flagship product, Vascepa, which is used to treat high triglyceride levels.

Average Trading Volume: 98,458

Technical Sentiment Signal: Strong Sell

Current Market Cap: $212.8M

For a thorough assessment of AMRN stock, go to TipRanks’ Stock Analysis page.